Item 1(a)
|
Name of issuer:
|
HOOKIPA Pharma Inc.
Item 1(b)
|
Address of issuers principal executive offices:
|
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York 10118
Item 2(a)
|
Name of person filing:
|
Takeda Pharmaceutical Company Limited
Takeda Pharmaceuticals
International AG
Takeda Pharmaceuticals U.S.A., Inc.
Takeda
Ventures, Inc.
Item 2(b)
|
Address of principal business office or, if none, residence:
|
Takeda Pharmaceutical Company Limited
1-1,
Nihonbashi-Honcho
2-Chome,
Chuo-ku,
Tokyo
103-8668,
Japan
Takeda Pharmaceuticals International AG
Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Zurich, Switzerland
Takeda Pharmaceuticals U.S.A., Inc. One Takeda Parkway, Deerfield, IL 60015, USA
Takeda Ventures, Inc. 435 Tasso Street, Suite 300, Palo Alto, CA 94301, USA
Takeda Pharmaceutical Company Limited Japan
Takeda
Pharmaceuticals International AG Switzerland
Takeda Pharmaceuticals U.S.A., Inc. United States
Takeda Ventures, Inc. United States
Item 2(d)
|
Title of class of securities:
|
Common Stock, par value $0.0001 per share
43906K 100
Item 3.
|
If this statement is filed pursuant to
§§240.13d-1(b)
or
240.13d-2(b)
or (c), check whether the person filing is a:
|
Not applicable.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: See the responses to Item 9 on the attached cover pages.
(b) Percent of class: See the responses to Item 11 on the attached cover pages.
(c) Number of shares as to which the person has:
(i) Sole
power to vote or to direct the vote: See the responses to Item 5 on the attached cover pages.
Page 6 of 8 pages